GlassScriptPhysician profile
Trena Stoute
NPI 1588003719
$1,832.94
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $380 · 2021: $557 · 2022: $671 · 2023: $24.00 · 2024: $40.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $345.33 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $204.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $195.60 | 2019-2022 | |
| Astellas Pharma US INC | $125.97 | 2019-2022 | |
| Array Biopharma INC | $98.20 | 2021-2022 | |
| Genentech USA, INC. | $81.33 | 2019-2022 | |
| Adc Therapeutics America, INC. | $77.75 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $62.64 | 2019-2021 | |
| Myovant Sciences INC. | $59.17 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $52.84 | 2021 | |
| Daiichi Sankyo INC. | $51.22 | 2020-2022 | |
| Gilead Sciences, INC. | $49.61 | 2022-2024 | |
| Pfizer INC. | $46.04 | 2021-2022 | |
| Seagen INC. | $44.07 | 2020-2022 | |
| Genzyme Corporation | $42.91 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $29.10 | 2020 | |
| Glaxosmithkline, LLC. | $29.07 | 2020-2022 | |
| Emd Serono, INC. | $26.13 | 2020 | |
| Genmab U.S., INC. | $24.00 | 2023 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $23.60 | 2021 | |
| Celgene Corporation | $22.09 | 2021 | |
| Mirati Therapeutics, INC. | $21.47 | 2024 | Krazati |
| Karyopharm Therapeutics INC. | $20.47 | 2022 | |
| Amgen INC. | $16.86 | 2021 | |
| Lilly USA, LLC | $16.17 | 2022 | |
| Myriad Genetic Laboratories, INC. | $15.58 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.55 | 2022 | |
| Morphosys, US INC. | $13.04 | 2021 | |
| Puma Biotechnology, INC. | $12.61 | 2020 | |
| Foundation Medicine, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trena Stoute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.